Robert Christopher Andrade Sells 106,844 Shares of Fennec Pharmaceuticals (TSE:FRX) Stock

Fennec Pharmaceuticals Inc. (TSE:FRX) insider Robert Christopher Andrade sold 106,844 shares of Fennec Pharmaceuticals stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of C$16.63, for a total value of C$1,776,815.72. Following the transaction, the insider owned 217,675 shares in the company, valued at approximately C$3,619,935.25. This represents a 32.92% decrease in their ownership of the stock.

Fennec Pharmaceuticals Price Performance

TSE FRX opened at C$17.00 on Friday. Fennec Pharmaceuticals Inc. has a one year low of C$7.59 and a one year high of C$17.64. The firm has a market cap of C$596.14 million, a P/E ratio of -141.67 and a beta of 3.55. The stock’s 50-day moving average is C$15.18 and its 200-day moving average is C$12.35.

Institutional Investors Weigh In On Fennec Pharmaceuticals

An institutional investor recently bought a new stake in Fennec Pharmaceuticals stock. Cornerstone Capital Inc. acquired a new position in shares of Fennec Pharmaceuticals Inc. (TSE:FRX) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 105,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,129,000. Cornerstone Capital Inc. owned 0.30% of Fennec Pharmaceuticals as of its most recent SEC filing. Hedge funds and other institutional investors own 15.23% of the company’s stock.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom ( U.K. ) approval in October 2023 under the brand name PEDMARQSI®. In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, with rights to commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand.